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Neglected infectious diseases (NIDs)
attract little interest from commercial
companies that invest in diagnostics and
therapeutics, mainly because the people
that they affect are amongst the poorest in
the world, who cannot afford to pay for
them. Many commercial companies shy
away from manufacturing diagnostic tests
for NIDs because a return on investment is
not usually guaranteed.
It is therefore not surprising that for a
disease such as human African trypanoso-
miasis (HAT), or sleeping sickness, no
diagnostic test has ever been manufac-
tured under full registration by any
regulatory agency. Tests that are available
today are produced by academic institu-
tions, with no guarantee that good man-
ufacturing practice for in-vitro diagnostics
(GMP-IVD) is adhered to. The card
agglutination test for trypanosomiasis
(CATT), developed in 1978, is the primary
screening tool used in areas where Try-
panosoma brucei gambiense is endemic [1].
Detection of antibodies against trypano-
somes using CATT is a sensitive indicator
of infection. However, in populations
undergoing screening, where prevalence
of the disease is usually below 2% and
specificity of the CATT test is around
95%, a large number of positive results
turn out to be false-positives, and the
positive predictive value of the test is not
good enough for it to be used on its own to
guide treatment. The test is manufactured
using whole T. b. gambiense organisms
recovered from infected laboratory ani-
mals in a complex and risky process, has
inferior sensitivity in some disease foci, and
can be performed only by trained person-
nel. Furthermore, it is incapable of
differentiating between active and cured
infections, as antibodies tend to stay in the
blood for prolonged periods after patients
have been cured [2,3]. What is worse, no
similar test is available for T. b. rhodesiense
infection.
Until now, no successful attempt has
been made to transform the CATT into a
single-format lateral flow test (LFT), which
would make it more accessible to diagnos-
tics facilities. This could again be because
a LFT for HAT provides little promise for
a return on investment, especially if it is to
be delivered at a price that is affordable to
the public sector in endemic countries. Yet
for diseases that are comparatively more
attractive, such as tuberculosis (TB), HIV,
malaria, and avian and swine flu, there has
been more commercial interest. In the late
1990s, intense lobbying by endemic coun-
tries, the World Health Organization
(WHO) and the international community
resulted in a paradigm shift, when at the
beginning of this decade, the pharmaceu-
tical industry agreed to provide free drugs
for HAT, preventing a potentially embar-
rassing situation [4]. However, this good-
will could not be extended to diagnostics
as no company was manufacturing any
tests for HAT.
A private foundation in Switzerland, the
Foundation for Innovative New Diagnos-
tics (FIND), has devised a novel approach
towards development of diagnostic tests
for NIDs that is generating a lot of interest
in industry. FIND, established in 2003,
supports the development of diagnostic
tests for diseases of poverty, including TB,
HAT, and malaria. The unique manage-
ment structure of FIND comprises diag-
nostics programmes that exist as indepen-
dent vertical business units, supported by
expertise that cuts across them (Figure 1).
A hallmark of FIND’s style of project
management includes the structuring of
product development, evaluation, demon-
stration and implementation into phases
that are well defined, with deliverables and
milestones that must be met before
products can advance in the pipeline and
receive further investment (Figure 2). The
rigor of FIND’s project management has
been recognised through certification for
ISO 13485:2003 and 9001:2008, stan-
dards that are customary for in vitro
diagnostics (IVD) manufacturing compa-
nies, yet are a rare achievement for a non-
profit organisation.
During the first six years of existence,
FIND focused its efforts on a diagnostics
development approach that seeks tech-
nology platforms that are applicable to
more than one disease, and used this
knowledge to leverage technology devel-
opment companies to include NIDs in
such platforms. Diagnostic products that
have passed through development, evalu-
ation, and demonstration trials are inte-
grated into the public health sectors of
target countries in partnerships that
ensure their sustainable implementation.
This has enabled FIND to create a
network of partners spanning the entire
diagnostics development pipeline, from
discovery to implementation [5]. Lever-
aging its contribution to the collabora-
tions that are established during the
product development process, FIND ne-
gotiates access strategies that guarantee
sustained availability of high-quality tests
at affordable prices for the public and
non-profit private healthcare sectors. It
does this through a laboratory support
programme that provides an excellent
opportunity to strengthen capacity for
diagnosis of NIDs by ensuring introduc-
tion, adaptation, and adoption of the
most appropriate diagnostic technologies
into an integrated laboratory network.
Two FIND-supported technology plat-
forms that are applicable to more than
one disease have completed development
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HAT. The first, a light-emitting diode
(LED)–based fluorescence microscope de-
veloped for TB by FIND and Zeiss has
become an excellent tool for parasite
demonstration in HAT, and only re-
quired evaluation studies to prove its
worth [6]. Besides TB and HAT, the
microscope has great potential for other
indications such as malaria and leishman-
iasis (Figure 3). It is robust, affordable,
uses LED bulbs with a lifespan of more
than 10,000 hours, and does not require a
dark room. Since the bulbs use very little
energy, the microscope can be operated
using solar power, making it easy to use in
remote rural settings such as those where
these diseases occur. The microscope has
been successfully evaluated for HAT in
laboratories in Uganda and the Demo-
cratic Republic of the Congo (DRC),
using acridine orange (AO) as the label
[6]. Furthermore, the AO staining proce-
dure is faster than Giemsa (3 versus
45 minutes of incubation).
The number of trypanosomes in the
blood of HAT patients is usually low
(especially T. b. gambiense), and various
methods are used to concentrate the
parasites in order to see them under a
microscope. FIND has been working with
scientists at Makerere University, Uganda,
and have overcome this problem by
performing selective lysis of the red cells
in blood samples using ammonium chlo-
ride or commercial lysis buffers, without
affecting the integrity of parasites [7].
When the lysed samples are centrifuged
and the sediment is used to prepare
smears, the sensitivity of LED fluorescence
microscopy is greatly improved. Parasite
concentration by lysis of red cells has a
number of advantages over standard
parasitological methods used to concen-
trate trypanosomes: it is a simple and fast
technique, no cold chain is required, and
large volumes of blood (.5 ml) can be
lysed to enhance the sensitivity of trypano-
some detection. A combination of this
method with LED fluorescence microsco-
py has great potential for inclusion into the
HAT diagnostic algorithm. Indeed, clini-
cal evaluation of this method is set to start
at several sites in the DRC and Uganda in
2010. Sustainable manufacture of the
LED microscope is guaranteed, because
diseases such as TB will provide the
market.
The second technology, loop-mediated
isothermal amplification (LAMP) of
DNA, is a simple molecular method
developed by Eiken Chemical in Japan.
The LAMP test is a novel strategy for
DNA amplification that relies on the
auto-cycling strand displacement synthesis
of DNA by Bst DNA polymerase under
isothermal conditions (60–65uC) [8].
Since LAMP is carried out at a constant
temperature, a simple incubator such as a
water bath or heating block is sufficient
for DNA amplification. The reaction
shows high tolerance to biological prod-
ucts, such that DNA extraction is not
necessary. The technique uses a set of six
primers that recognise eight sections of
Figure 1. The management structure of FIND. Diagnostic programmes for various diseases operate as independent business units, supported
by expertise that cuts across the programmes. SAC: scientific advisory committee, CSO: chief scientific officer, STO: senior technology officer, CFO:
chief finance officer, SOO: senior operations officer, SPO: senior policy officer.
doi:10.1371/journal.pntd.0000715.g001
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DNA by multiple primers makes LAMP
highly sensitive and increases specificity,
efficiency, and rapidity. The results of a
test can be inspected visually by the
addition of the fluorescent dye SYBR
Green 1 or calcein (Figure 4), or by
measurement of turbidity derived from a
precipitate of magnesium pyrophosphate
in the reaction mixture.
FIND and its academic partners, Mur-
doch and Obihiro Universities, have
successfully developed a LAMP test for
sub-genus Trypanozoon using the random
insertion mobile element (RIME) se-
quences [9] and one for T. b. rhodesiense
based on the serum resistance associated
(SRA) gene [10]. Meanwhile, FIND had
been working with Eiken on a LAMP test
for TB long before they started the HAT
programme [11], and has taken advan-
tage of this relationship with Eiken to
include the LAMP test for HAT in this
diagnostic platform. Evaluation of manu-
factured LAMP tests for HAT using
blood as the starting material is to be
carried out in experimental and clinical
settings in 2010. Further studies to
determine the feasibility of using saliva
or urine as the starting sample will also be
carried out.
The LAMP test can be performed by
staff with minimal experience in molecu-
lar biology. Given its high sensitivity,
specificity, speed, and ease of use, LAMP
could become a good test for field
diagnosis of HAT and confirmation of
cure in sub-Saharan Africa, where facil-
ities are limited. FIND is working with the
Institute of Primate Research (IPR) in
Nairobi, Kenya, to determine the feasi-
bility of using this method to confirm cure
after successful treatment, and predict
relapses in case of treatment failure [12].
Its application as a test of cure will
however depend on the rate at which
DNA from dead parasites is cleared from
a host after treatment. The test could also
be useful for epidemiological studies and
disease elimination programmes. It also
appears that with a little more effort,
LAMP tests for Buruli ulcer, Chagas
disease, and leishmaniasis, other NIDs
that FIND has taken an interest in, could
be included on the same platform, whose
commercial development targets diseases
such as TB and malaria. This platform
has therefore provided a good opportuni-
ty to diagnose several diseases from the
same sample.
The lateral flow test (LFT) provides yet
another platform that is widely used in
indications such as pregnancy, malaria,
etc. In yet another first for FIND, an LFT
for screening for HAT could soon be
available. An initiative spearheaded by
FIND has been screening candidate anti-
gens for their potential in detecting both
T. b. gambiense and T. b. rhodesiense,t ob e
used for developing a specific and sensitive
antibody detection LFT [13]. The test will
be developed at minimal additional cost in
a new partnership between FIND and
Standard Diagnostics, Republic of Korea,
a commercial company that has become a
global leader in development of IVDs for
infectious diseases.
The initiatives described here will result
in novel tests for HAT that are more
sensitive and specific, and are easier to use
than those that are currently available.
Application of the tests could lead to an
acceleration of the present efforts in
surveillance and control of the disease.
Such tools will also be invaluable in setting
up better recruitment of patients and
confirmation of cure in clinical studies by
Figure 2. Phases in the diagnostics development pipeline that are implemented by FIND. A product must meet pre-determined criteria to
advance from one stage to the next.
doi:10.1371/journal.pntd.0000715.g002
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in compound development for HAT.
While FIND may have devised an
innovative approach to solve the problem
of technology development by investing in
platforms that apply to commercially
attractive diseases and to ‘‘piggy-back’’
the NIDs on them, the challenge that
remains is to increase the investment in
strategies that will make these diagnostics
accessible, so that they can easily reach the
‘‘neglected people’’ at little or no cost.
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Figure 4. The result of a LAMP test is
determined by visual inspection of re-
action tubes. Positive samples exhibit bright
green fluorescence (right) and are thus easily
distinguished from negative ones (left) (cour-
tesy of Eiken Chemical).
doi:10.1371/journal.pntd.0000715.g004
Figure 3. The Primo Star iLED microscope can be used to visualize various pathogens.
(A) Tubercle bacilli stained with auramine O (courtesy of CDC). (B) A thin blood smear stained with
acridine orange showing trypanosomes (orange) alongside red blood cells (green) (courtesy of
Zeiss). (C) Malaria parasites (small orange structures) inside red blood cells (green) of a baboon
experimentally infected with Plasmodium knowlesi and stained with acridine orange. White blood
cells also stain orange (blood smear courtesy of Dr. Maina Ngotho, Institute of Primate Research,
Nairobi). (D) Cultured Leishmania donovani promastigotes (orange with flagella) stained with
acridine orange (slide courtesy of Dr. Maina Ngotho).
doi:10.1371/journal.pntd.0000715.g003
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